Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ConvaTec ( (GB:CTEC) ) just unveiled an update.
ConvaTec Group PLC has executed a share buyback transaction, purchasing 948,052 ordinary shares as part of its $300 million share buyback program announced in August 2025. The shares were bought at prices ranging between 238.80 and 241.80 pence and will be held in treasury. This move aims to optimize the company’s capital structure and potentially enhance shareholder value by reducing the number of shares in circulation, thereby increasing earnings per share.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £2.82 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Spark’s Take on GB:CTEC Stock
According to Spark, TipRanks’ AI Analyst, GB:CTEC is a Outperform.
ConvaTec’s overall stock score reflects its strong financial performance, which is the most significant factor. The company’s robust revenue growth, profitability, and cash flow management are key strengths. However, technical analysis indicates mixed signals, and the valuation suggests the stock may be overvalued, which could limit future gains. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on GB:CTEC stock, click here.
More about ConvaTec
ConvaTec Group PLC operates in the medical products and technologies industry, focusing on the development and supply of products for wound care, ostomy care, continence and critical care, and infusion devices. The company targets healthcare providers and patients across various markets globally.
Average Trading Volume: 7,652,082
Technical Sentiment Signal: Buy
Current Market Cap: £4.81B
See more insights into CTEC stock on TipRanks’ Stock Analysis page.